Table 2.

Individual data.

ID	Sex	Time(months)	Prior TSS	Prior RDT	Dose variation (mg) a	Daily doses	Baseline ACTH	Baseline X > ULNUFC	Final X > ULNUFC	Final therapeutic response	Comorbidities	Altered liver function	Regular use	Intolerance/adverse effects	Outcome
1	F	42	Yes	No	400–600	3	41	0.13	0.4b	Complete	SAH and DM	No	Yes	No	Continued use
2	F	7	Yes	Yes	100–200	2	88	1	0.79b	Complete	SAH	No	Yes	Yes, nausea	Interrupted due to intolerance
3	F	5	No, pre-TSS use	No	200–400	2		5.4	0.39	Partial	SAH	Yes—drug hepatitis	Yes	Yes, hepatitis	Interrupted due to drug hepatitis
4	F	120	No	No	200–800	4	76	2.92	0.8b	Complete	–	No	Yes	Yes	Pseudotumor cerebri resolved with acetazolamide
5	F	126	Yes	No	150–1,000	4 to 5	129	0.05	-0.36	Complete	Dyslipidemia	No	Yes	No	Continued use
6	F	90	Yes	No	300–1,000	4 to 5	26	3.9	-0.7	Complete	SAH and DM	No	Yes	No	Underwent radiotherapy
7	F	63	Yes	No	400–1,000	3	148	5.8	-0.46	Complete	SAH	No	Yes	No	Underwent radiotherapy
8	F	26	No, pre-TSS use	No	600–800	4	106	2.56	0.39b	No response	SAH and DM	No	Yes	No	Underwent TSS
9	F	81	Yes	No	600–1,200	5	24	22.2	5.68b	No response	SAH	No	Yes	Yes	Underwent bilateral adrenalectomy
10	F	86	Yes	No	400–1,200	4 to 5	65	0.72	-0.47	Complete	–	Important and isolated elevation of GGT	Yes	No	Underwent new TSS
11	F	51	Yes	No	400–800	2	48	-0.68 b	-0.8	Complete	SAH and dyslipidemia	Discrete and isolated elevation of GGT	Yes	No	Continued use
12	F	14 days	No	No	600	3	121	4.3	3.5	No response	SAH and DM	No	Yes	No	Underwent TSS
13	F	15	Yes	No	600–800	4	50	0.1	-0.06	Complete	SAH, DM and dyslipidemia	Discrete and isolated elevation of GGT	No	No	Continued use
14	F	85	Yes	No	200–800	4	37	2.11	-0.38b	No response	SAH	Elevation of TGO and GPT, discontinued medication	Yes	Yes	Underwent radiotherapy
15	F	119	Yes	No	600–1,200	4 to 5	40	2.31	1.3	Partial	SAH, DM and dyslipidemia	Discrete and isolated elevation of GGT	Yes	No	Underwent radiotherapy
16	F	14	Yes	Yes	600	3	300	0.27	-0.06b	Partial	SAH and dyslipidemia	No	Yes	No	Underwent bilateral adrenalectomy
17	M	29	Yes	No	400–600	3	54	1.62	-0.6	Complete	–	No	Yes	Yes, loss of appetite	Ketoconazole suspended due to loss of appetite
18	F	5	Yes	No	400	2	65	- 0.08 b	-0.8	Complete	SAH and DM	Discrete and isolated GGT uptake	Yes	No	Underwent radiosurgery
19	M	42	No, pre-TSS use	No	400–1,200	2 to 6	51	3.67	2.8	No response	SAH	Discrete elevation of TGO and GGT	No	No	Underwent TSS
20	F	6	Yes	No	400	2	115	3.9	2b	No response	–	No	Yes	No	Lost to follow-up
21	F	125	Yes	Yes	400–1,000	3 to 5	84	1.34	-0.02	Complete	SAH	No	Yes	Yes, diarrhea	Underwent bilateral adrenalectomy
22	M	34	Yes	Yes	100	2		0.3	-0.8	Complete	SAH, DM and dyslipidemia	No	Yes	No	Lost to follow-up
23	F	53	Yes	No	200–600	2 to 4	61	1.19	-0.6	Complete	SAH and DM	No	Yes	Yes, dizziness	Continued use
24	M	3	Yes	No	600	3	1,696	34	0.8b	Complete	SAH	No	Yes	No	Underwent bilateral adrenalectomy
25	F	133	Yes	No	400	2	89	0.4	-0.8	Complete	SAH	No	Yes	No	Continued use
26	F	23	Yes	No	200–800	2 to 4	57	0.53	-0.08	No response	–	No	Yes	No	Underwent radiosurgery
27	F	38	No, pre-TSS use	No	400–600	2 to 3	102	4.1	-0.3	Complete	SAH and DM	No	Yes	Yes, dizziness and loss of appetite	Continued use
28	M	111	Yes	No	400—1,200	3 to 4	75	3.9	-0.8	Complete	SAH	Discrete elevation of TGO, GPT, and GGT	Yes	Yes, nausea	Underwent radiotherapy
29	F	8	No, pre-TSS use	No	300	3	92	2.2	0.8b	No response	SAH	No	Yes	No	Underwent TSS
30	F	132	Yes	No	200–400	2 to 3	20	-0.2 b	-0.5	Complete	SAH, DM and dyslipidemia	No	Yes	No	Continued use
31	F	40	Yes	No	400–800	2 to 3	21	0.7	-0.99	Complete	SAH and DM	No	Yes	No	Continued use
32	F	64	Yes	No	400–800	2 to 4	41	-0.7 b	-0.6	Complete	–	Discrete and isolated elevation of GGT	Yes	No	Underwent radiotherapy
33	F	173	Yes	Yes	400–800	2 to 4	40	0.05	-0.5	Complete	SAH	No	No	No	Pregnancy continued using ketoconazole without complications

RDT, radiotherapy; DM, diabetes mellitus; GGT, gamma glutamyl transferase; SAH, systemic arterial hypertension; TGO, oxaloacetic transaminase; GPT, glutamate–pyruvate transaminase; TSS, transsphenoidal surgery; ULN, upper limit of normal.

^aThe highest dose used was not necessarily the final dose used.

^bIn these patients, the criterion used to consider active hypercortisolism was late night salivary cortisol and/or elevated 1 mg dexamethasone overnight.